Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/83532
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMustafa, S.en
dc.contributor.authorSee, H.en
dc.contributor.authorSeeber, R.en
dc.contributor.authorArmstrong, S.en
dc.contributor.authorWhite, C.en
dc.contributor.authorSabatino, V.en
dc.contributor.authorAyoub, M.en
dc.contributor.authorPfleger, K.en
dc.date.issued2012en
dc.identifier.citationJournal of Biological Chemistry, 2012; 287(16):12952-12965en
dc.identifier.issn0021-9258en
dc.identifier.issn1083-351Xen
dc.identifier.urihttp://hdl.handle.net/2440/83532-
dc.description.abstractWe have provided the first evidence for specific heteromerization between the α1A-adrenoceptor (α1AAR) and CXC chemokine receptor 2 (CXCR2) in live cells. α1AAR and CXCR2 are both expressed in areas such as the stromal smooth muscle layer of the prostate. By utilizing the G protein-coupled receptor (GPCR) heteromer identification technology on the live cell-based bioluminescence resonance energy transfer (BRET) assay platform, our studies in human embryonic kidney 293 cells have identified norepinephrine-dependent β-arrestin recruitment that was in turn dependent upon co-expression of α1AAR with CXCR2. These findings have been supported by co-localization observed using confocal microscopy. This norepinephrine-dependent β-arrestin recruitment was inhibited not only by the α1AR antagonist Terazosin but also by the CXCR2-specific allosteric inverse agonist SB265610. Furthermore, Labetalol, which is marketed for hypertension as a nonselective β-adrenoceptor antagonist with α1AR antagonist properties, was identified as a heteromer-specific-biased agonist exhibiting partial agonism for inositol phosphate production but essentially full agonism for β-arrestin recruitment at the α1AAR-CXCR2 heteromer. Finally, bioluminescence resonance energy transfer studies with both receptors tagged suggest that α1AAR-CXCR2 heteromerization occurs constitutively and is not modulated by ligand. These findings support the concept of GPCR heteromer complexes exhibiting distinct pharmacology, thereby providing additional mechanisms through which GPCRs can potentially achieve their diverse biological functions. This has important implications for the use and future development of pharmaceuticals targeting these receptors.en
dc.description.statementofresponsibilitySanam Mustafa, Heng B. See, Ruth M. Seeber, Stephen P. Armstrong, Carl W. White, Sabatino Ventura, Mohammed Akli Ayoub, and Kevin D. G. Pflegeren
dc.language.isoenen
dc.publisherAmer Soc Biochemistry Molecular Biology Incen
dc.rights© 2012 by The American Society for Biochemistry and Molecular Biology, Inc.en
dc.subject7-Helix Receptor; Adrenergic Receptor; Allosteric Regulation; Arrestin; Chemokines; G Protein-coupled Receptors (GPCR); Heteromeren
dc.titleIdentification and profiling of novel a1A-adrenoceptor-CXC chemokine receptor 2 heteromeren
dc.typeJournal articleen
dc.identifier.rmid0020138129en
dc.identifier.doi10.1074/jbc.M111.322834en
dc.identifier.pubid14476-
pubs.library.collectionMedical Sciences publicationsen
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidMustafa, S. [0000-0002-8677-5151]en
Appears in Collections:Medical Sciences publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.